| Autor: |
Emine Merve Savaş, Seda Yılmaz, Ayşe Asena Başer Dikyar, Zübeyde Nur Özkurt, Ramazan Öcal, Ferda Can, Sezgin Pepeler, Lale Aydın Kaynar, Sanem Gökçen, Abdulkerim Yıldız, Murat Albayrak, Sema Karakuş, Özcan Çeneli, Münci Yağcı |
| Jazyk: |
angličtina |
| Rok vydání: |
2023 |
| Předmět: |
|
| Zdroj: |
Turkish Journal of Hematology, Vol 40, Iss 4, Pp 236-241 (2023) |
| Druh dokumentu: |
article |
| ISSN: |
1308-5263 |
| DOI: |
10.4274/tjh.galenos.2023.2023.0194 |
| Popis: |
Objective: The discovery of imatinib was a milestone for chronic myeloid leukemia (CML). As the life expectancy of CML patients has approached that of the general population, research has shifted towards improving quality of life and economic considerations. After 2010, it was shown that some patients could maintain molecular response even after discontinuing imatinib. This national multicenter prospective cohort study aimed to observe the long-term consequences of discontinuing imatinib therapy in adult chronicphase CML patients. Materials and Methods: We enrolled 41 CML patients from 4 different centers in this non-randomized single-arm trial. Molecular responses of all patients were re-evaluated using real-time polymerase chain reaction at a single center. The median follow-up time after imatinib discontinuation was 48 months (minimum-maximum: 6-81 months). Results: The rate of molecular relapse-free survival at 48 months was 33.2% (confidence interval: 48.2-18.2). Twenty-seven of 41 patients lost their major molecular response, treatment was started again, and deep molecular response was re-achieved with imatinib in all cases. There was no significant relationship between molecular relapse and clinical factors such as duration of treatment or molecular response status. Discontinuing imatinib resulted in savings of approximately 4,392,000 Turkish lira or 245,150 US dollars. Conclusion: Tyrosine kinase inhibitor discontinuation with close molecular monitoring is a safe option and provides important national economic benefits for chronic phase CML patients. This approach should be considered for all eligible patients. This is the first tyrosine kinase inhibitor discontinuation study from Türkiye. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
